NR1H4 and biliary atresia: Indeed, a series of FXR ligands have been executed in clinical trials, such as OCA (Intercept), LJN452 (Novartis), GS9674 (Gilead), and EDP305 (Enanta), as treatments for FXR-mediated diseases, including primary biliary cholangitis (PBC), NASH, primary sclerosing cholangitis (PSC), or biliary atresia.